Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering's shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia ...

NEW YORK (CBS.MW) -- Shares of Schering-Plough climbed Tuesday after some analysts said a new cholesterol-lowering drug could help the company recover from its current regulatory and financial woes.

Information regarding Schering-Plough’s directors and executive officers is available in Schering-Plough’s proxy statement for its 2008 annual meeting of shareholders, filed with the SEC on ...

Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in a deal that gives Merck key new businesses, access to a promising pipeline of new products and the chance to further cut costs ...

The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries. Through the date of filing this 10-Q, Schering-Plough, the joint ...

Schering-Plough Corp. said yesterday it has agreed to pay $435 million and will plead guilty to conspiracy to settle a federal investigation into marketing of its drugs for unapproved uses and ...

KENILWORTH, N.J. Schering-Plough has completed its buyout of the biopharmaceutical company Organon BioSciences NV for about $14.43 billion in cash.. This is the completion of a deal first ...

Schering-Plough last year agreed to divest several lines of veterinary products to win regulatory approval of its $14.4 billion purchase of Organon BioSciences. Today, the Kenilworth drugmaker ...

Schering-Plough said late Wednesday that Richard Jay Kogan will retire as chief executive and president by April 22, 2003. The drugmaker added that, as of Wednesday, Kogan has resigned his ...

Schering-Plough Corp.’s fourth-quarter earnings surged 62% as the combined sales of its Vytorin and Zetia cholesterol drugs jumped to $1.1 billion. Net income rose to $204 million, or 12 cents a ...